Here we show that that the HIF-1α/VEGF-A response in T cells has direct effects on cancer growth, progression, and vascularization, suggesting that therapeutic strategies targeting HIF-1α or VEGF-A signaling in the tumor microenvironment will affect cancer therapy generally and immunotherapy specifically. This evidence concerns the gene VEGFA and cancer.